DEF 14A: Enveric Biosciences Sets Date for 2024 Annual Stockholders Meeting

Enveric Biosciences will hold its 2024 Annual Meeting of Stockholders virtually on May 28, 2024, to elect directors, vote on executive compensation, ratify the appointment of the independent auditor, and conduct an advisory vote on the frequency of future executive compensation votes.

Summary

• Enveric Biosciences, Inc. will hold its 2024 Annual Meeting of Stockholders on May 28, 2024, at 10:00 a.m. Eastern Time, as a virtual meeting.
• Stockholders of record as of April 1, 2024, are entitled to vote.
• The meeting will include the election of six directors, an advisory vote on executive compensation (Say-on-Pay), ratification of Marcum LLP as the independent auditor for the fiscal year ending December 31, 2024, and an advisory vote on the frequency of future Say-on-Pay votes.
• The Board recommends voting FOR the election of all six director nominees, FOR the Say-on-Pay proposal, FOR the Auditor Ratification proposal, and for ONE YEAR on the Say-on-Frequency proposal.
• Proxy materials are available online, and stockholders can vote via the Internet, telephone, or mail.
• The company has retained Kingsdale Advisors to assist in the solicitation of proxies for a fee of $10,100 plus reimbursement of expenses.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The Board's recommendations and expressions of gratitude contribute to a slightly positive sentiment.

Positives

• The Board recommends voting FOR all six director nominees.
• The Board recommends voting FOR the Say-on-Pay proposal.
• The Board recommends voting FOR the Auditor Ratification proposal.
• The Board recommends voting ONE YEAR for the Say-on-Frequency proposal.
• The virtual format of the Annual Meeting is designed to enhance stockholder access, participation and communication.

Future Outlook

The document outlines the proposals to be voted on at the 2024 Annual Meeting and provides recommendations from the Board regarding these proposals.

Management Comments

• On behalf of the Board, I urge you to submit your vote as soon as possible, even if you currently plan to attend the Annual Meeting online.
• Thank you for your ongoing support of our Company.

Industry Context

Proxy statements are standard documents for publicly traded companies, providing transparency and enabling shareholder participation in corporate governance.

Comparison to Industry Standards

• The proposals outlined in the proxy statement, such as the election of directors, say-on-pay vote, and auditor ratification, are standard items for annual meetings of publicly traded companies.
• The virtual format of the annual meeting is becoming increasingly common, aligning with trends towards greater accessibility and cost-effectiveness.
• The engagement of a proxy solicitation firm like Kingsdale Advisors is a typical practice to ensure sufficient shareholder participation and quorum attainment.

Related Party Transactions

• The Company and David Johnson, the Company's former Executive Chairman, entered into a consulting agreement on January 1, 2023, where Mr. Johnson earns $23,833 per month ($286,000 per annum) over the term of the January Agreement.

Stakeholder Impact

• Shareholders have the opportunity to vote on key corporate governance matters.
• The outcome of the votes will influence the composition of the Board and executive compensation practices.
• Employees are indirectly affected by the decisions made at the Annual Meeting, as they impact the overall direction and management of the company.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on May 28, 2024, and announce the results.

Key Dates

Keywords

annual meeting, proxy statement, stockholders, directors, executive compensation, auditor ratification, virtual meeting, voting, Enveric Biosciences